Diet-first guidance sharpens management of canine chronic enteropathy: full analysis

Diet-first guidance sharpens management of canine chronic enteropathy

A new review in the Journal of Small Animal Practice is putting dietary therapy back at the center of canine chronic enteropathy management. In the paper, published online January 25, 2026, Aarti Kathrani and colleagues provide evidence-based recommendations for managing normoalbuminaemic dogs with chronic enteropathy, concluding that diet alone is effective in roughly half of referral cases and that success rates improve when clinicians pursue multiple systematic diet trials. (pubmed.ncbi.nlm.nih.gov)

That message lands at a time when chronic enteropathy care is becoming more structured. A newly published ACVIM-endorsed consensus statement and systematic review notes that the field now has better-quality studies on diagnosis and treatment, including dietary options and adjunctive therapies used alongside first-line nutrition. In other words, the new JSAP review doesn't arrive in a vacuum; it adds a more nutrition-focused framework to a broader push for clearer CE treatment algorithms. (pubmed.ncbi.nlm.nih.gov)

The review itself emphasizes several practical points. First, clinicians shouldn't view diet as a one-and-done intervention. The authors say outcomes improve when multiple diet trials are used in a systematic way, and they recommend basing decisions on the individual dog's documented response to each nutritional intervention rather than on rigid, arbitrary trial rules. Second, in dogs with only a partial response, the most effective diet should generally be maintained while other treatments are added, with the goal of preserving any dietary benefit and potentially lowering drug needs and adverse effects. The authors also note that published evidence is still incomplete in places, so some recommendations are informed by expert clinical experience as well as the literature. (pubmed.ncbi.nlm.nih.gov)

That approach is consistent with the direction of earlier and emerging CE nutrition research. A 2022 review on dietary management of chronic enteropathy in dogs described nutrition as a mainstay of care and highlighted hydrolyzed, limited-ingredient, and fat-restricted strategies. More recently, an open-label study of an extensively hydrolyzed, amino acid-based extruded diet reported strong short-term clinical responses in dogs that had already failed previous diet trials, although the authors stressed that the findings were preliminary and need confirmation in larger prospective work. Educational materials from the Purina Institute similarly advise considering a second dietary trial with a different nutritional strategy before moving on to antibiotics or intestinal biopsy in stable dogs. (pubmed.ncbi.nlm.nih.gov)

Industry and expert interest in this space is clearly growing, but so is scrutiny around evidence quality and competing interests. The author list for the JSAP review includes investigators from major academic centers as well as the Royal Canin Research Centre, and the ACVIM consensus statement's disclosures reflect extensive relationships across the veterinary nutrition and diagnostics sectors, including Royal Canin, Purina, IDEXX, and others. That doesn't invalidate the guidance, but it does make study design, transparency, and independent replication especially important as practices translate recommendations into protocols. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinarians, the biggest implication may be operational rather than theoretical. Chronic enteropathy cases can escalate quickly to antimicrobials, immunosuppressives, referral workups, or endoscopy, especially when the first food change fails. This review argues for a more disciplined nutrition pathway: select diets strategically, run trials long enough, measure response consistently, and keep the best-performing diet in place even when adding other therapies. That could improve remission rates, support antimicrobial stewardship, and help practices counsel pet parents more clearly about expectations, adherence, and the need for follow-up. (pubmed.ncbi.nlm.nih.gov)

The focus on normoalbuminaemic dogs is also clinically relevant because these patients may appear less urgent than dogs with protein-losing enteropathy, yet still carry meaningful long-term risk if disease remains refractory. A recent long-term outcome study in dogs with chronic inflammatory enteropathy without moderate to severe hypoalbuminemia found that treatment subtype, discharge therapy, and remission status were associated with GI-related death, suggesting that even dogs outside the classic PLE phenotype deserve structured, proactive management. (academic.oup.com)

What to watch: The next step is likely integration, not disruption: expect clinicians, specialty services, and nutrition-focused education groups to use this review alongside the 2026 ACVIM guidance to refine diet trial sequencing, duration, and escalation thresholds. The biggest open questions are which nutritional approach should come first in specific CE phenotypes, how to define failure before switching diets, and which recommendations hold up as larger prospective and independent studies are published. (pubmed.ncbi.nlm.nih.gov)